Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor)
Antoni X. Torres‐Collado, Jeffrey R. Knott, Ali R. Jazirehi
Cancers (2018) Vol. 10, Iss. 6, pp. 157-157
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, et al.
Drug Resistance Updates (2019) Vol. 47, pp. 100646-100646
Closed Access | Times Cited: 112
Metabolic flexibility in melanoma: A potential therapeutic target
Maria Rosaria Ruocco, Angelica Avagliano, Giuseppina Granato, et al.
Seminars in Cancer Biology (2019) Vol. 59, pp. 187-207
Closed Access | Times Cited: 77
BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation
Drishti Rathod, Yige Fu, Ketan Patel
European Journal of Pharmaceutical Sciences (2019) Vol. 138, pp. 105039-105039
Closed Access | Times Cited: 62
Ameloblastoma: A succinct review of the classification, genetic understanding and novel molecular targeted therapies
Hongyi Adrian Shi, Chee Wee Ng, Chong Teck Kwa, et al.
The Surgeon (2020) Vol. 19, Iss. 4, pp. 238-243
Closed Access | Times Cited: 58
Inhibitors of HSP90 in melanoma
Aleksandra Mielczarek-Lewandowska, Mariusz L. Hartman, Małgorzata Czyż
APOPTOSIS (2019) Vol. 25, Iss. 1-2, pp. 12-28
Open Access | Times Cited: 57
A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma
Yangzi Tian, Weinan Guo
Medical Science Monitor (2020) Vol. 26
Open Access | Times Cited: 56
Systemic Therapies for Advanced Melanoma
Leonora Bomar, Aditi Senithilnathan, Christine Ahn
Dermatologic Clinics (2019) Vol. 37, Iss. 4, pp. 409-423
Closed Access | Times Cited: 52
Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
Mariusz L. Hartman, Małgorzata Sztiller-Sikorska, Anna Gajos-Michniewicz, et al.
Cells (2020) Vol. 9, Iss. 1, pp. 142-142
Open Access | Times Cited: 49
Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic Ameloblastoma
Maxime Brunet, Emmanuel Khalifa, Antoîne Italiano
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 45
Emerging Roles of SKP2 in Cancer Drug Resistance
Ting Wu, Xinsheng Gu, Hongmei Cui
Cells (2021) Vol. 10, Iss. 5, pp. 1147-1147
Open Access | Times Cited: 36
Drug-adapted cancer cell lines as preclinical models of acquired resistance
Martin Michaelis, Mark N. Wass, Jindřich Činátl
Cancer Drug Resistance (2019)
Open Access | Times Cited: 37
Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications
Wei Liu, Paweł Stachura, Haifeng C. Xu, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 33
NECTIN4: A Novel Therapeutic Target for Melanoma
Yuka Tanaka, Maho Murata, Che-Hung Shen, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 976-976
Open Access | Times Cited: 30
Biofabrication of a tri-layered 3D-bioprinted CSC-based malignant melanoma model for personalized cancer treatment
Julia López de Andrés, Marta Ruiz-Toranzo, Cristina Antich, et al.
Biofabrication (2022) Vol. 15, Iss. 3, pp. 035016-035016
Open Access | Times Cited: 21
Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers
Bernhard Biersack, Bianca Nitzsche, Michael Höpfner
Cancer Drug Resistance (2025)
Open Access
Novel HSP90-PI3K Dual Inhibitor Suppresses Melanoma Cell Proliferation by Interfering with HSP90-EGFR Interaction and Downstream Signaling Pathways
Qian Zhao, Hongping Zhu, Xin Xie, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 5, pp. 1845-1845
Open Access | Times Cited: 32
AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
Ishani Das, Helge Gad, Lars Bräutigam, et al.
Cell Death and Differentiation (2020) Vol. 27, Iss. 7, pp. 2081-2098
Open Access | Times Cited: 24
Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma
Xintao Yang, Feng Hu, Jessica Aijia Liu, et al.
Oncogene (2020) Vol. 39, Iss. 20, pp. 4061-4076
Open Access | Times Cited: 23
Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2
Ting Wu, Chengyun Li, Changlong Zhou, et al.
Cell Biology and Toxicology (2022) Vol. 39, Iss. 5, pp. 2381-2399
Closed Access | Times Cited: 13
Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets
József Tóvári, Diána Vári-Mező, Sára Eszter Surguta, et al.
Cells (2023) Vol. 12, Iss. 14, pp. 1919-1919
Open Access | Times Cited: 7
A20 promotes melanoma progression via the activation of Akt pathway
Jinyuan Ma, Huina Wang, Sen Guo, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 9
Open Access | Times Cited: 18
Fear of Progression, Anxiety, and Depression in Patients With Advanced Melanoma in the COVID-19 and Post-COVID-19 Era
Xiaowen Wang, Min Li, Qiong Shi, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 10
Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides as Potential Multi-Target Antiproliferative Agents
Lamya H. Al-Wahaibi, Anber F. Mohammed, Mostafa Abdelrahman, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 1039-1039
Open Access | Times Cited: 6
The Oncogenic Signaling Pathways in BRAF-Mutant Melanoma Cells Are Modulated by Naphthalene Diimide-Like G-Quadruplex Ligands
Marta Recagni, Martina Tassinari, Filippo Doria, et al.
Cells (2019) Vol. 8, Iss. 10, pp. 1274-1274
Open Access | Times Cited: 14
Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance
Silvana Sandri, Luis Roberto Masao Watanabe, Érica Aparecida de Oliveira, et al.
Pharmacological Research (2020) Vol. 159, pp. 104998-104998
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top